Faster recall reporting for drugs and devices

Summary#

These are final amendments to the Food and Drug Regulations and the Medical Devices Regulations (registered June 17, 2024, published July 3, 2024) that change how recalls, establishment licences and some finished-product testing rules work. They require faster, more detailed reporting and record-keeping for many recalls, let Health Canada impose targeted licence conditions, and create targeted testing exemptions for certain biologics and short‑lived radiopharmaceuticals. Most of the rules come into force on the 180th day after registration (with some parts effective on June 17, 2024).

What it does#

• Strengthens recall reporting for drugs:
  • Manufacturers or importers who decide to recall must notify Health Canada within 24 hours and give more product, distribution and risk details.
  • Provide a recall strategy within 72 hours, and a final report within 30 days after the recall is completed.
  • Extends reporting rules to active ingredients and to people ordered by the Minister to recall (for example, wholesalers or retailers).
• Changes for medical device recalls:
  • Firms must report device recalls to Health Canada only when the device is likely to cause injury (roughly Type I and II), reducing reports for very low‑risk (Type III) actions.
  • Firms must notify Health Canada within 24 hours of deciding to recall, provide a full report when starting the recall, and a completion report within 30 days.
  • New record‑keeping rules require manufacturers, importers and distributors to keep detailed recall records for the device’s projected life plus 2 years (manufacturers must keep records for as long as they sell the device or that projected life plus 2 years, whichever is longer).
• Establishment licence (DEL / MDEL) updates:
  • Require licence holders and applicants to provide updated contact details (including email) and to tell Health Canada of prior business names; report changes within 15 days.
  • Give the Minister power to impose or change specific terms and conditions on a medical device establishment licence at any time, after considering feasibility and risk.
• Other changes:
  • Replace a static list of foreign regulatory authorities in the drug rules with an ambulatory list published online (to reflect current mutual‑recognition agreements).
  • Create conditional exemptions from some finished‑product testing for certain gene/cell therapies and radiopharmaceuticals, when safety evidence and transport/storage controls are documented.

Who's affected#

• Drug and medical device manufacturers and importers — especially those who may need to start recalls or who handle gene/cell therapies or radiopharmaceuticals.
• Distributors, packagers/labellers and wholesalers who participate in finished product testing or recalls.
• Retailers and other sellers who could be ordered by the Minister to recall a product.
• Holders and applicants of medical device establishment licences (MDELs) and drug establishment licences (DELs), including many small businesses.
• Health Canada and its inspectors (responsible for receiving reports, keeping lists, and implementing terms/conditions).

If the source is unclear about a specific business or product, the rules above apply generally and Health Canada’s guidance will fill in details.

Why it matters#

• Faster, clearer reporting: regulators get critical recall information earlier (initial notice in 24 hours, plan in 72 hours, results in 30 days). That helps protect patients and lets officials track recall progress.
• Less paperwork for very low‑risk device fixes: companies no longer must report every minor corrective action to Health Canada, which aligns Canada with other regulators and reduces reputational and administrative burden for industry.
• Better tools to manage risks without halting supply: the new ability to place targeted terms and conditions on a medical device licence can address specific problems without shutting a company down completely, helping avoid shortages.
• Easier updates and international alignment: the online list of recognized foreign regulators and the adjusted testing rules aim to speed access to certain complex therapies and reduce delays caused by impractical testing (for example, short‑lived radiopharmaceuticals or single‑patient cell therapies).
• Numbers from the regulatory analysis (estimates):
  • Expected annual benefits: $5,817,052 per year (annualized) or $40,856,537 present value over ten years.
  • Estimated industry cost: $125,923 per year (annualized) or $884,433 present value over ten years.
  • Estimated government cost: $80,715 per year (annualized) or $566,912 present value over ten years.
  • Net estimated benefit (present value): $39,405,192 over ten years.

These are administrative and oversight changes rather than new safety standards. The rules are already final; guidance documents will clarify how companies should comply.